Posted in | News

Mathy Construction and Ergon Asphalt + Emulsions Secure Patent for Hot Mix Asphalt Production Process

Ergon Asphalt and Emulsions, Inc., (Ergon), and Mathy Construction Co. of Onalaska, WI announced today the award of a patented process that allows for the production and placement of conventional hot mix asphalt (HMA) at reduced temperatures of up to 75⁰ F.

This surfactant enabled patented process which is compatible with Non-Modified, Polymer Modified and PPA containing asphalt binders was co-developed by Mathy Technology & Engineering (MTE) and Paragon Technical Services, Inc., and has been trademarked REVIX™. REVIX™ will be exclusively marketed internationally by MWV Specialty Chemicals Division’s Asphalt Innovations team as MWV EVOTHERM® 3G.

EVOTHERM 3G offers many advantages over other WMA processes including significant energy savings and environmental benefits over conventional HMA. These benefits include the ability to increase RAP and RAS content due to the reduced binder aging. It can reduce emissions of organic compounds by up to 60% at the paver screed, and provide HMA contractor’s energy savings ranging from 10% to 25% without physical Hot Mix Plant modifications. EVOTHERM 3G does not alter the specified SHRP PG graded binder when added compared to other WMA technologies.

Ergon and Mathy believe that EVOTHERM 3G provides workers an environmentally friendly alternative to the existing HMA and current “water only” WMA processes. This contractor friendly additive will aid in the expansion of the warm-mix asphalt category worldwide.

Source: http://www.mwv.com

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.